Efficacy and Safety of Bimekizumab in Psoriatic Arthritis Patients with Significant Skin and Nail Involvement Over One Year - Takeaways - MDSpire

Efficacy and Safety of Bimekizumab in Psoriatic Arthritis Patients with Significant Skin and Nail Involvement Over One Year

  • By

  • Diamant Thaçi

  • Akihiko Asahina

  • Wolf-Henning Boehncke

  • Alice B. Gottlieb

  • Mark Lebwohl

  • Richard B. Warren

  • Heather Edens

  • Barbara Ink

  • Rajan Bajracharya

  • Jason Coarse

  • Joseph F. Merola

  • December 12, 2025

  • 0 min

Share

  • 1

    Bimekizumab significantly improved disease symptoms in PsA patients with skin and nail involvement compared to placebo at week 16.

  • 2

    Improvements in disease domains with bimekizumab were sustained through week 52 for both biologic-naïve and TNFi-IR patients.

  • 3

    The treatment was well tolerated, with no new safety concerns identified during the study.

  • 4

    Bimekizumab's efficacy in treating PsA with concomitant plaque-type psoriasis and nail involvement is clinically relevant.

  • 5

    This study provides valuable data for clinicians in selecting effective treatments for patients with severe PsA symptoms.

Original Source(s)

Efficacy and Safety of Bimekizumab in Psoriatic Arthritis Patients with Significant Skin and Nail Involvement Over One Year

  • by Diamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Heather Edens, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola

  • December 12, 2025

Related Content

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies